
  
    
      
        Introduction_NNP
        Cancer_NN evolves_NNS from_IN the_DT accumulation_NN of_IN mutations_NNS and_CC
        the_DT deregulation_NN of_IN two_CD classes_NNS of_IN genes_NNS ,_, oncogenes_NNS and_CC
        tumor_NN suppressor_NN genes_NNS ._. The_DT large_JJ majority_NN of_IN breast_NN
        cancers_NNS arise_VBP in_IN epithelia_NN of_IN the_DT breast_NN ,_, and_CC they_PRP are_VBP
        thought_VBN to_TO evolve_VB from_IN hyperplasia_NN with_IN atypia_NN to_TO carcinoma_NN
        in_IN situ_NN ,_, invasive_JJ carcinoma_NN ,_, and_CC ,_, finally_RB ,_, metastatic_JJ
        disease_NN ._. The_DT molecular_JJ mechanisms_NNS leading_VBG to_TO breast_NN
        malignancies_NNS are_VBP unclear_JJ ,_, but_CC many_JJ genetic_JJ abnormalities_NNS
        and_CC epigenetic_JJ factors_NNS have_VBP been_VBN implicated_VBN ,_, including_VBG
        changes_NNS affecting_VBG known_VBN tumor_NN suppressor_NN genes_NNS (_( 
        p_NN 53_CD ,_, 
        BRCA_NNP 1_CD ,_, BRCA_NNP 2_CD ,_, 
        PTEN_NNP /_NN MMAC_NNP 1_CD /_NN TEP_NNP 1_LS )_) and_CC proto-oncogenes_JJ 
        (_( neu_NN /_NN ErbB_NNP 2_CD /_NN HER_NNP 2_CD ,_, 
        ErbB_NNP 1_CD /_NN EGFR_NNP ,_, 
        PRAD-_NNP 1_CD /_NN cyclin_NN D_NNP 1_CD ,_, 
        Mdm_NNP 2_CD ,_, and_CC 
        c-myc_JJ )_) [_NN reviewed_VBN in_IN ref_NN ._. 1_LS ]_NN ._.
        The_DT gene_NN product_NN of_IN 
        PTEN_NNP (_( 
        phosphatase_NN and_CC 
        tensin_NN homolog_NN deleted_VBN from_IN
        chromosome_NN 10_CD )_) is_VBZ a_DT lipid_NN phosphatase_NN that_WDT reverses_VBZ the_DT
        activities_NNS of_IN phosphatidylinositol_NN 3_CD -_: kinase_NN (_( PI_NNP 3_CD K_NNP )_) by_IN
        dephosphorylating_VBG the_DT D_NNP 3_CD position_NN of_IN its_PRP$ lipid_NN products_NNS ,_,
        phosphatidylinositol-_NN 3_CD ,_, 4_CD bis-phosphate_JJ (_( PtdIns_NNP (_( 3_CD ,_, 4_LS )_) P_NN 2_LS )_) ,_,
        phosphatidylinositol-_NN 3_CD ,_, 5_CD bis-phosphate_JJ (_( PtdIns_NNP (_( 3_CD ,_, 5_LS )_) P_NN 2_LS )_) ,_, and_CC
        3_CD ,_, 4_CD ,_, 5_CD -_: tri-phosphate_JJ (_( PtdIns_NNP (_( 3_CD ,_, 4_CD ,_, 5_LS )_) P_NN 3_LS )_) [_NN 2_CD ,_, 3_CD ]_NN ,_, the_DT elevated_VBD
        levels_NNS of_IN which_WDT are_VBP linked_VBN to_TO the_DT transforming_VBG ability_NN of_IN
        PI_NNP 3_CD K_NNP [_NN reviewed_VBN in_IN ref_NN ._. 4_LS ]_NN ._.
        PtdIns_NNP (_( 3_CD ,_, 4_LS )_) P_NN 2_CD and_CC PtdIns_NNP (_( 3_CD ,_, 4_CD ,_, 5_LS )_) P_NN 3_CD recruit_VB AKT_NNP (_( also_RB
        known_VBN as_IN protein_NN kinase_NN B_NNP [_NN PKB_NNP ]_NN )_) to_TO the_DT membrane_NN through_IN
        the_DT N-_NNP terminal_NN pleckstrin_NN homology_NN (_( PH_NNP )_) domain_NN of_IN AKT_NNP
        [_NN reviewed_VBN in_IN ref_NN ._. 5_LS ]_NN ._. Membrane_NNP localization_NN renders_NNS AKT_NNP
        permissive_JJ to_TO phosphorylation_NN by_IN phosphatidyl_NN
        inositol-dependent_JJ kinases_NNS ,_, PDK_NNP 1_CD and_CC PDK_NNP 2_CD ,_, at_IN Thr_NNP 308_CD within_IN
        the_DT activation_NN loop_NN and_CC at_IN Ser_NNP 473_CD near_IN the_DT carboxyl_NN
        terminus_JJ ._. Phosphorylation_NNP activates_NNS the_DT kinase_NN domain_NN of_IN
        AKT_NNP ,_, which_WDT ,_, in_IN turn_NN ,_, phosphorylates_NNS target_VBP proteins_NNS on_IN
        serine_NN and_CC threonine_NN residues_NNS ._. Substrates_NNP of_IN AKT_NNP include_VBP
        glycogen_NN synthase_NN kinase_NN 3_CD (_( GSK_NNP 3_LS )_) ,_, p_NN 70_CD /_NN S_NNP 6_CD kinase_NN ,_, BAD_NNP ,_,
        Caspase_NNP 9_CD ,_, 4_CD E-BP_NNP 1_CD ,_, IκB_NNP kinase_NN α_NN and_CC members_NNS of_IN the_DT Forkhead_NNP
        transcription_NN family_NN [_NN reviewed_VBN in_IN ref_NN ._. 6_CD ,_, 7_CD ]_NN ._. Constitutive_NNP
        membrane_NN localization_NN of_IN AKT_NNP leads_VBZ to_TO its_PRP$ deregulated_VBN
        activation_NN and_CC can_MD induce_VB oncogenic_JJ transformation_NN [_NN 8_CD ,_,
        9_CD ]_NN ._.
        All_DT three_CD human_JJ members_NNS of_IN the_DT AKT_NNP family_NN are_VBP
        over-produced_JJ in_IN various_JJ human_JJ cancers_NNS ._. 
        AKT_NNP 1_CD is_VBZ over-expressed_JJ in_IN gastric_JJ
        adenocarcinomas_NNS and_CC breast_NN cancer_NN cell_NN lines_NNS ,_, 
        AKT_NNP 2_CD is_VBZ amplified_VBN and_CC over-expressed_JJ
        in_IN pancreatic_JJ ,_, ovarian_NN ,_, and_CC breast_NN cancers_NNS ,_, and_CC 
        AKT_NNP 3_CD is_VBZ upregulated_JJ in_IN estrogen_NN
        receptor-deficient_JJ breast_NN cancer_NN and_CC in_IN
        androgen-independent_JJ prostate_NN cell_NN lines_NNS [_NN reviewed_VBN in_IN ref_NN ._.
        6_CD ]_NN ._.
        Consistent_NNP with_IN the_DT role_NN of_IN PTEN_NNP as_IN a_DT lipid_NN phosphatase_NN ,_,
        
        PTEN_NNP -_: deficient_NN human_NN and_CC mouse_NN cells_NNS
        have_VBP elevated_VBD levels_NNS of_IN intracellular_NN PtdIns_NNP (_( 3_CD ,_, 4_CD ,_, 5_LS )_) P_NN 3_CD [_NN 10_CD ,_,
        11_CD ]_NN and_CC demonstrate_VB constitutive_JJ activation_NN of_IN AKT_NNP in_IN the_DT
        absence_NN of_IN growth_NN factors_NNS [_NN 12_CD ,_, 13_CD ,_, 14_CD ]_NN ._. The_DT relationship_NN
        between_IN components_NNS of_IN this_DT pathway_NN is_VBZ also_RB conserved_JJ in_IN
        flies_VBZ and_CC worms_NNS ._.
        A_DT germline_NN mutation_NN in_IN 
        PTEN_NNP is_VBZ associated_VBN with_IN
        multi-neoplastic_JJ ,_, autosomally_RB dominant_JJ syndromes_NNS in_IN humans_NNS ,_,
        such_JJ as_IN Cowden_NNP disease_NN and_CC Bannayan-_NNP Zonana_NNP syndrome_NN (_( also_RB
        known_VBN as_IN Bannayan-_NNP Riley-_NNP Ruvalcaba_NNP syndrome_NN )_) ,_, and_CC 20_CD -_: 50_CD %_NN of_IN
        affected_VBN females_NNS in_IN these_DT families_NNS develop_VBP breast_NN cancer_NN [_NN
        15_CD ,_, 16_CD ,_, 17_CD ]_NN ._. The_DT 
        PTEN_NNP gene_NN is_VBZ also_RB frequently_RB deleted_VBN
        or_CC mutated_VBN in_IN a_DT variety_NN of_IN sporadic_JJ human_JJ malignancies_NNS ,_,
        such_JJ as_IN glioblastoma_NN and_CC carcinomas_NNS of_IN the_DT prostate_NN ,_,
        endometrium_NN and_CC breast_NN ._. Although_IN somatic_JJ mutations_NNS in_IN the_DT
        gene_NN have_VBP been_VBN detected_VBN in_IN only_RB about_IN 1_CD %_NN of_IN breast_NN cancers_NNS ,_,
        loss_NN of_IN heterozygosity_NN (_( LOH_NNP )_) at_IN the_DT 
        PTEN_NNP locus_JJ (_( 10_CD q_NN 23_CD )_) is_VBZ frequently_RB
        found_VBN (_( approximately_RB 40_CD %_NN )_) ,_, and_CC 33_CD %_NN of_IN breast_NN tumors_NNS have_VBP no_DT
        detectable_JJ ,_, or_CC reduced_VBD ,_, levels_NNS of_IN the_DT protein_NN product_NN [_NN 18_CD ,_,
        19_CD ,_, 20_CD ,_, 21_CD ,_, 22_CD ]_NN ._.
        Three_CD independent_JJ mouse_NN lines_NNS carrying_VBG inactivating_VBG 
        Pten_NNP mutations_NNS have_VBP been_VBN made_VBN [_NN 23_CD ,_,
        24_CD ,_, 25_CD ]_NN ._. All_DT mice_NNS homozygous_JJ for_IN these_DT 
        Pten_NNP mutations_NNS die_VBP during_IN early_JJ
        embryogenesis_NNS ._. By_IN 6_CD months_NNS of_IN age_NN ,_, heterozygous_JJ mice_NNS
        develop_VBP tumors_NNS of_IN the_DT lymphoid_NN system_NN ,_, colon_NN ,_, uterus_NN ,_, and_CC
        adrenal_NN medulla_NN with_IN very_RB high_JJ penetrance_NN ,_, and_CC tumors_NNS of_IN
        the_DT prostate_NN and_CC thyroid_NN with_IN lower_JJR penetrance_NN ._. While_IN
        benign_JJ mammary_JJ lesions_NNS ,_, usually_RB fibroadenomas_NNS ,_, are_VBP found_VBN in_IN
        female_JJ mice_NNS after_IN 7_CD months_NNS of_IN age_NN ,_, few_JJ animals_NNS develop_VBP
        ductal_NN carcinomas_NNS [_NN KP_NNP and_CC RP_NNP ,_, unpublished_JJ ;_: 26_CD ]_NN ,_, which_WDT
        account_VBP for_IN over_IN 85_CD %_NN of_IN human_JJ breast_NN cancers_NNS ._.
        In_IN an_DT effort_NN to_TO develop_VB a_DT model_NN for_IN studying_VBG the_DT effects_NNS
        of_IN 
        Pten_NNP inactivation_NN in_IN mammary_JJ
        oncogenesis_NNS ,_, we_PRP have_VBP introduced_VBN an_DT additional_JJ genetic_JJ
        alteration_NN ,_, an_DT MMTV-_NNP 
        Wnt-_NNP 1_CD transgene_NN ,_, by_IN breeding_VBG 
        Pten_NNP heterozygotes_NNS [_NN 25_CD ]_NN with_IN MMTV-_NNP 
        Wnt-_NNP 1_CD transgenic_JJ (_( TG_NNP )_) mice_NNS [_NN 27_CD ]_NN ._.
        Female_NNP mice_NNS harboring_VBG the_DT 
        Wnt-_NNP 1_CD transgene_NN develop_VB extensive_JJ
        mammary_JJ hyperplasia_NN early_RB in_IN life_NN ,_, and_CC 50_CD %_NN of_IN them_PRP develop_VBP
        mammary_JJ ductal_NN carcinomas_NNS by_IN 6_CD months_NNS of_IN age_NN [_NN 27_CD ]_NN ._. This_DT
        transgene_NN has_VBZ been_VBN shown_VBN to_TO collaborate_VB with_IN 
        Fgf-_NNP 3_CD and_CC inactivation_NN of_IN 
        p_NN 53_CD to_TO accelerate_VB the_DT appearance_NN of_IN
        mammary_JJ tumors_NNS [_NN 28_CD ,_, 30_CD ]_NN ._. After_IN a_DT mutant_JJ allele_NN of_IN 
        Pten_NNP was_VBD crossed_VBN into_IN 
        Wnt-_NNP 1_CD TG_NNP mice_NNS ,_, we_PRP found_VBD that_IN ductal_NN
        carcinomas_NNS appeared_VBD earlier_RBR than_IN either_DT alteration_NN alone_RB
        and_CC that_IN LOH_NNP at_IN the_DT 
        Pten_NNP locus_JJ occurred_VBD in_IN the_DT majority_NN
        of_IN these_DT tumors_NNS ,_, suggesting_VBG a_DT selective_JJ growth_NN advantage_NN in_IN
        cells_NNS that_WDT lack_NN 
        Pten_NNP functions_NNS ._.
      
      
        Results_NNS
        
        Wnt-_NNP 1_CD TG_NNP mice_NNS have_VBP been_VBN used_VBN to_TO
        assess_VB the_DT functions_NNS of_IN a_DT number_NN of_IN genetic_JJ lesions_NNS in_IN
        breast_NN carcinogenesis_NNS because_IN tumors_NNS appear_VBP with_IN
        predictable_JJ kinetics_NNS ._. The_DT median_JJ age_NN at_IN which_WDT tumors_NNS are_VBP
        detected_VBN is_VBZ 5_CD -_: 6_CD months_NNS in_IN MMTV-_NNP 
        Wnt-_NNP 1_CD TG_NNP females_NNS [_NN 27_CD ,_, 28_CD ,_, 30_CD ,_, 31_CD ]_NN ._.
        After_IN one_CD mutated_VBN allele_NN of_IN 
        Pten_NNP was_VBD bred_VBN into_IN this_DT transgenic_JJ
        line_NN ,_, tumors_NNS appeared_VBD significantly_RB earlier_RBR than_IN in_IN sibling_VBG
        females_NNS harboring_VBG only_RB a_DT MMTV-_NNP 
        Wnt-_NNP 1_CD transgene_NN (_( P_NN <_NN 0_CD ._. 001_CD ,_, Fig_NNP ._.
        1_LS A_DT )_) ._. Fifty_NNP percent_NN of_IN 
        Pten_NNP +_NN /_NN -_: ,_, 
        Wnt-_NNP 1_CD TG_NNP female_JJ mice_NNS formed_VBD tumors_NNS by_IN
        3_CD ._. 5_CD months_NNS ,_, 2_CD ._. 5_CD months_NNS earlier_RBR than_IN 
        Wnt-_NNP 1_CD TG_NNP mice_NNS (_( Fig_NNP ._. 1_LS A_DT )_) ._. While_IN it_PRP
        took_VBD one_CD year_NN for_IN the_DT entire_JJ cohort_NN (_( 15_CD )_) of_IN 
        Wnt-_NNP 1_CD TG_NNP females_NNS with_IN a_DT wild_JJ type_NN 
        Pten_NNP background_NN to_TO develop_VB tumors_NNS ,_,
        all_DT 
        Wnt-_NNP 1_CD TG_NNP ,_, 
        Pten_NNP +_NN /_NN -_: females_NNS showed_VBD tumors_NNS by_IN 5_CD
        months_NNS of_IN age_NN ._. Five_CD each_DT of_IN 
        Pten_NNP +_NN /_NN -_: mice_NNS without_IN a_DT 
        Wnt-_NNP 1_CD transgene_NN were_VBD monitored_VBN for_IN 7_CD
        months_NNS and_CC 10_CD ._. 5_LS months_NNS ,_, but_CC none_NN developed_VBD any_DT palpable_JJ
        mammary_JJ lesions_NNS ._. These_DT observations_NNS differ_VBP from_IN a_DT recent_JJ
        report_NN that_IN one_CD of_IN the_DT other_JJ two_CD 
        Pten_NNP +_NN /_NN -_: lines_NNS develops_VBZ fibroadenomas_NNS
        and_CC adenocarcinomas_NNS in_IN the_DT mammary_JJ tissue_NN after_IN 7_CD months_NNS of_IN
        age_NN [_NN 26_CD ]_NN ._. The_DT lack_NN of_IN a_DT mammary_JJ phenotype_NN in_IN our_PRP$ studies_NNS
        could_MD be_VB due_JJ to_TO differences_NNS in_IN the_DT targeting_VBG constructs_NNS ,_,
        the_DT genetic_JJ backgrounds_NNS ,_, or_CC even_RB environmental_JJ agents_NNS ._.
        By_IN one_CD year_NN of_IN age_NN ,_, approximately_RB 15_CD %_NN of_IN 
        Wnt-_NNP 1_CD TG_NNP males_NNS have_VBP been_VBN reported_VBN to_TO
        develop_VB mammary_JJ tumors_NNS [_NN 27_CD ,_, 28_CD ,_, 31_CD ]_NN ._. In_IN our_PRP$ cross_NN ,_, one_CD of_IN
        the_DT four_CD tumors_NNS from_IN 
        Wnt-_NNP 1_CD TG_NNP males_NNS ,_, in_IN an_DT otherwise_RB wild_JJ
        type_NN background_NN ,_, was_VBD a_DT mammary_JJ carcinoma_NN ;_: the_DT other_JJ three_CD
        tumors_NNS were_VBD salivary_JJ in_IN origin_NN ,_, with_IN a_DT similar_JJ
        histopathology_NN to_TO the_DT mammary_JJ lesion_NN ._. The_DT appearance_NN of_IN
        tumors_NNS was_VBD greatly_RB accelerated_VBN in_IN the_DT 
        Pten_NNP heterozygous_JJ background_NN (_( Fig_NNP ._.
        1_LS B_NNP )_) ._. Fifty_NNP percent_NN of_IN males_NNS developed_VBD tumors_NNS by_IN 5_CD ._. 5_CD months_NNS
        of_IN age_NN ,_, and_CC all_DT developed_VBN tumors_NNS within_IN 10_CD months_NNS ._. As_IN in_IN
        the_DT case_NN of_IN 
        Wnt-_NNP 1_CD TG_NNP male_JJ mice_NNS without_IN 
        Pten_NNP mutations_NNS ,_, the_DT majority_NN of_IN
        tumors_NNS (_( 14_CD /_NN 22_CD )_) arose_VBD in_IN the_DT salivary_JJ tissue_NN ;_: only_RB a_DT small_JJ
        number_NN of_IN tumors_NNS (_( 2_CD /_NN 22_CD )_) were_VBD mammary_JJ in_IN origin_NN ,_, and_CC ,_,
        interestingly_RB ,_, some_DT (_( 6_CD /_NN 22_CD )_) were_VBD bilateral_JJ or_CC unilateral_JJ
        muzzle_NN tumors_NNS of_IN epithelial_NN origin_NN ,_, similar_JJ
        histopathologically_RB to_TO lesions_NNS found_VBD in_IN mammary_JJ and_CC
        salivary_JJ tissues_NNS ._.
        To_TO determine_VB if_IN the_DT wild_JJ type_NN allele_NN of_IN 
        Pten_NNP was_VBD inactivated_JJ in_IN tumors_NNS
        arising_VBG in_IN a_DT 
        Pten_NNP +_NN /_NN -_: background_NN ,_, 11_CD tumors_NNS from_IN 
        Wnt-_NNP 1_CD TG_NNP ,_, 
        Pten_NNP +_NN /_NN -_: mice_NNS were_VBD examined_VBN for_IN LOH_NNP
        by_IN Southern_NNP hybridization_NN ._. Seven_CD tumors_NNS had_VBD lost_VBN the_DT wild_JJ
        type_NN 
        Pten_NNP allele_NN (_( see_VB Fig_NNP ._. 2_LS for_IN an_DT example_NN
        of_IN the_DT analysis_NN )_) ._. This_DT result_NN suggests_VBZ that_IN ,_, in_IN
        tumorigenesis_NNS ,_, cells_NNS that_WDT lack_NN a_DT functional_JJ allele_NN of_IN 
        Pten_NNP have_VBP a_DT significant_JJ proliferative_JJ
        advantage_NN over_IN the_DT cells_NNS that_WDT retain_VBP the_DT normal_JJ copy_NN of_IN 
        Pten_NNP ._.
        Histological_NNP examination_NN showed_VBD that_IN tumors_NNS from_IN 
        Wnt-_NNP 1_CD TG_NNP mice_NNS ,_, regardless_RB of_IN 
        Pten_NNP status_NN ,_, were_VBD adenocarcinomas_NNS
        with_IN cribriform_NN ,_, cystic_JJ and_CC focal_JJ papillary_JJ growth_NN
        patterns_NNS ._. However_RB ,_, 3_CD of_IN the_DT 6_CD tumors_NNS that_WDT were_VBD 
        Wnt-_NNP 1_CD TG_NNP ,_, 
        Pten_NNP +_NN /_NN -_: with_IN LOH_NNP appeared_VBD to_TO have_VB a_DT
        higher_JJR nuclear_JJ grade_NN ,_, more_RBR cellular_JJ stroma_NN and_CC a_DT more_RBR
        infiltrative_JJ pattern_NN compared_VBN to_TO the_DT tumors_NNS without_IN a_DT 
        Pten_NNP defect_NN (_( Fig_NNP ._. 3_LS )_) ,_, suggesting_VBG a_DT
        more_RBR aggressive_JJ phenotype_NN ._.
        In_IN human_JJ cancer_NN ,_, a_DT tumor_NN suppressor_NN gene_NN can_MD be_VB
        inactivated_JJ by_IN mutations_NNS ,_, chromosomal_NN loss_NN ,_, promoter_NN
        silencing_VBG ,_, and_CC other_JJ means_NNS ._. To_TO determine_VB if_IN the_DT Pten_NNP
        protein_NN was_VBD produced_VBN in_IN 
        Wnt-_NNP 1_CD TG_NNP ,_, 
        Pten_NNP +_NN /_NN -_: tumors_NNS that_WDT did_VBD not_RB undergo_VB
        LOH_NNP ,_, sections_NNS were_VBD analyzed_VBN using_VBG an_DT immunohistochemical_JJ
        assay_NN with_IN a_DT polyclonal_NN rabbit_NN antibody_NN ._. Abundant_NNP amounts_NNS
        of_IN Pten_NNP were_VBD detected_VBN in_IN mammary_JJ ducts_NNS from_IN wild_JJ type_NN mice_NNS ._.
        Pten_NNP was_VBD detected_VBN ,_, at_IN reduced_VBN levels_NNS ,_, in_IN both_DT hyperplastic_JJ
        ducts_NNS and_CC mammary_JJ tumors_NNS that_WDT did_VBD not_RB have_VB LOH_NNP at_IN the_DT 
        Pten_NNP allele_NN (_( Fig_NNP ._. 4_LS )_) ,_, suggesting_VBG that_IN
        Pten_NNP was_VBD ,_, indeed_RB ,_, made_VBN from_IN the_DT second_JJ allele_NN ._. Similar_JJ low_JJ
        levels_NNS of_IN Pten_NNP were_VBD also_RB detected_VBN in_IN mammary_JJ ductal_NN
        epithelial_NN cells_NNS in_IN 
        Pten_NNP heterozygous_JJ mice_NNS that_WDT did_VBD not_RB
        have_VB a_DT 
        Wnt-_NNP 1_CD transgene_NN ,_, suggesting_VBG that_IN the_DT 
        Wnt-_NNP 1_CD transgene_NN does_VBZ not_RB influence_VB 
        Pten_NNP expression_NN ._. As_IN expected_VBN ,_, Pten_NNP
        was_VBD not_RB detected_VBN in_IN tumors_NNS that_WDT had_VBD undergone_VBN LOH_NNP at_IN the_DT 
        Pten_NNP locus_JJ (_( Fig_NNP ._. 4_LS E_NNP )_) ._.
        Inactivation_NNP of_IN 
        Pten_NNP promotes_VBZ membrane_NN recruitment_NN of_IN
        AKT_NNP and_CC its_PRP$ subsequent_JJ activation_NN by_IN phosphorylation_NN at_IN
        Ser_NNP 473_CD and_CC Thr_NNP 308_CD [_NN 10_CD ,_, 11_CD ,_, 13_CD ]_NN ._. All_DT three_CD human_JJ isoforms_NNS
        of_IN AKT_NNP have_VBP been_VBN found_VBN to_TO be_VB deregulated_VBN in_IN human_JJ breast_NN
        cancer_NN cells_NNS [_NN 32_CD ,_, 33_CD ,_, 34_CD ]_NN ._. To_TO determine_VB if_IN activated_VBN AKT_NNP
        was_VBD increased_VBN in_IN tumors_NNS that_WDT had_VBD a_DT 
        Pten_NNP defect_NN ,_, these_DT sections_NNS were_VBD
        stained_JJ using_VBG an_DT antibody_NN that_IN specifically_RB detects_NNS AKT_NNP 1_CD
        phosphorylated_JJ at_IN Ser_NNP 473_CD (_( and_CC AKT_NNP 2_CD and_CC AKT_NNP 3_CD phosphorylated_JJ
        at_IN equivalent_NN sites_NNS )_) ._. Tumors_NNP that_WDT were_VBD 
        Wnt-_NNP 1_CD TG_NNP ,_, 
        Pten_NNP +_NN /_NN -_: with_IN LOH_NNP displayed_VBD staining_VBG
        of_IN phosphorylated_JJ AKT_NNP (_( Fig_NNP ._. 5_LS A_DT )_) ._. Surprisingly_RB ,_, the_DT staining_VBG
        was_VBD patchy_NN ,_, suggesting_VBG additional_JJ factors_NNS may_MD be_VB required_VBN
        for_IN AKT_NNP activation_NN ._. As_IN expected_VBN ,_, phosphorylated_JJ AKT_NNP was_VBD
        undetectable_JJ in_IN hyperplastic_JJ ducts_NNS ,_, in_IN tumors_NNS from_IN 
        Wnt-_NNP 1_CD TG_NNP ,_, 
        Pten_NNP +_NN /_NN +_NN mice_NNS ,_, and_CC tumors_NNS from_IN 
        Wnt-_NNP 1_CD TG_NNP ,_, 
        Pten_NNP +_NN /_NN -_: mice_NNS that_WDT retained_VBD the_DT wild_JJ
        type_NN allele_NN (_( Fig_NNP ._. 5_LS B_NNP &_CC C_NNP )_) ._.
        Several_JJ apoptotic_JJ pathways_NNS may_MD be_VB inhibited_VBD upon_IN
        activation_NN of_IN AKT_NNP ,_, promoting_VBG maintenance_NN and_CC survival_NN of_IN
        tumor_NN cells_NNS ._. Cellular_NNP proliferation_NN may_MD also_RB be_VB enhanced_VBN by_IN
        activated_VBN AKT_NNP ,_, which_WDT inhibits_NNS p_NN 27_CD and_CC GSK-_NNP 3_CD (_( leading_VBG to_TO
        stabilization_NN of_IN cyclin_NN D_NNP 1_LS )_) [_NN 35_CD ]_NN ._. However_RB ,_, tumors_NNS from_IN 
        Wnt-_NNP 1_CD TG_NNP ,_, 
        Pten_NNP +_NN /_NN +_NN mice_NNS have_VBP low_JJ apoptotic_JJ
        rates_NNS (_( 40_CD ±_NN 16_CD per_IN digital_JJ camera_NN field_NN using_VBG a_DT 20_CD x_SYM
        objective_NN )_) and_CC high_JJ proliferation_NN rates_NNS (_( 53_CD %_NN ±_NN 11_CD )_) ._. Neither_DT
        apoptotic_JJ nor_CC proliferation_NN rates_NNS were_VBD affected_VBN by_IN the_DT
        status_NN of_IN 
        Pten_NNP when_WRB measured_VBN by_IN the_DT TUNEL_NNP
        (_( terminal_NN deoxynucleotidyltransferase-mediated_JJ UTP_NNP end_NN
        labeling_VBG )_) assay_NN ,_, which_WDT labels_VBZ the_DT ends_NNS of_IN fragmented_JJ DNA_NNP
        present_JJ in_IN apoptotic_JJ cells_NNS ,_, and_CC immunohistochemical_JJ
        staining_VBG for_IN Ki_NNP 67_CD ,_, a_DT cell_NN proliferation_NN marker_NN (_( data_NNS not_RB
        shown_VBN )_) ._.
        Most_JJS 
        Wnt-_NNP 1_CD TG_NNP mice_NNS (_( 38_CD /_NN 49_CD )_) developed_VBN only_RB
        one_CD palpable_JJ tumor_NN regardless_RB of_IN 
        Pten_NNP status_NN ._. Fifty-three_NNP of_IN 55_CD single_JJ
        sections_NNS from_IN 
        Pten_NNP +_NN /_NN +_NN glands_NNS that_WDT were_VBD free_JJ of_IN a_DT
        palpable_JJ mass_NN did_VBD not_RB show_VB any_DT lesions_NNS more_JJR advanced_VBD than_IN
        ductal_NN hyperplasia_NN ._. However_RB ,_, at_IN the_DT time_NN of_IN sacrifice_NN ,_, the_DT
        majority_NN (_( 50_CD /_NN 56_CD )_) of_IN glands_NNS from_IN 
        Wnt-_NNP 1_CD TG_NNP 
        ,_, Pten_NNP +_NN /_NN -_: mice_NNS had_VBD intra-ductal_JJ
        squamous_JJ lesions_NNS of_IN various_JJ sizes_NNS (_( Fig_NNP ._. 3_LS D_NNP )_) ._. These_DT squamous_JJ
        lesions_NNS were_VBD usually_RB multi-focal_JJ and_CC located_VBN both_DT at_IN the_DT
        periphery_NN of_IN the_DT adenocarcinomas_NNS and_CC in_IN other_JJ mammary_JJ
        glands_NNS free_JJ of_IN adenocarcinomas_NNS ._.
        Since_IN 
        Pten_NNP mutations_NNS are_VBP usually_RB found_VBN in_IN
        advanced_VBD tumors_NNS ,_, and_CC the_DT protein_NN has_VBZ been_VBN suggested_VBN to_TO
        inhibit_VB cell_NN spreading_VBG ,_, migration_NN ,_, and_CC invasion_NN [_NN 36_CD ,_, 37_CD ]_NN ,_,
        it_PRP is_VBZ possible_JJ that_IN the_DT tumors_NNS from_IN 
        Wnt-_NNP 1_CD TG_NNP ,_, 
        Pten_NNP +_NN /_NN -_: mice_NNS may_MD have_VB a_DT higher_JJR
        potential_JJ to_TO metastasize_NN than_IN those_DT from_IN mice_NNS carrying_VBG a_DT 
        Wnt-_NNP 1_CD transgene_NN in_IN a_DT wild_JJ type_NN 
        Pten_NNP background_NN ._. 
        Wnt-_NNP 1_CD TG_NNP mice_NNS occasionally_RB show_VBP
        lymphoid_NN or_CC pulmonary_JJ metastasis_NNS [_NN 27_CD ]_NN ,_, and_CC serial_NN
        sectioning_VBG of_IN lung_NN tissues_NNS from_IN the_DT animals_NNS reported_VBD here_RB
        revealed_VBN microsocopic_JJ metastatic_JJ foci_NN in_IN two_CD of_IN five_CD lungs_NNS
        from_IN 
        Wnt-_NNP 1_CD TG_NNP mice_NNS bearing_VBG primary_JJ tumors_NNS
        1_CD ._. 5_CD -_: 2_CD ._. 0_CD cm_NN in_IN size_NN ._. However_RB ,_, 
        Wnt-_NNP 1_CD TG_NNP mice_NNS and_CC the_DT 
        Wnt-_NNP 1_CD TG_NNP ,_, 
        Pten_NNP +_NN /_NN -_: mice_NNS harbored_JJ metastatic_JJ
        foci_NN at_IN similar_JJ frequencies_NNS (_( 5_CD /_NN 10_CD )_) ._. (_( Statistical_NNP evaluation_NN
        was_VBD not_RB performed_VBN because_IN the_DT sample_NN sizes_NNS were_VBD too_RB
        small_JJ ._. )_)
      
      
        Discussion_NNP
        Mouse_NNP models_NNS are_VBP valuable_JJ research_NN tools_NNS for_IN the_DT study_NN
        of_IN the_DT molecular_JJ mechanisms_NNS of_IN oncogenesis_NNS and_CC for_IN the_DT
        testing_NN and_CC screening_NN of_IN cancer_NN therapeutic_JJ agents_NNS targeted_VBN
        to_TO specific_JJ oncogenic_JJ lesions_NNS ._. In_IN order_NN to_TO produce_VB such_PDT a_DT
        model_NN for_IN studying_VBG the_DT effects_NNS of_IN 
        Pten_NNP mutations_NNS in_IN breast_NN cancer_NN ,_, we_PRP
        have_VBP crossed_VBN 
        Wnt-_NNP 1_CD TG_NNP mice_NNS to_TO mice_NNS heterozygous_JJ
        for_IN 
        Pten_NNP ._. Mice_NNS transgenic_JJ for_IN MMTV-_NNP 
        Wnt-_NNP 1_CD and_CC heterozygous_JJ for_IN 
        Pten_NNP developed_VBD mammary_JJ
        adenocarcinomas_NNS much_JJ earlier_JJR than_IN mice_NNS carrying_VBG either_CC
        lesion_NN alone_RB ._. The_DT majority_NN of_IN tumors_NNS in_IN 
        Wnt-_NNP 1_CD TG_NNP ,_, 
        Pten_NNP +_NN /_NN -_: mice_NNS had_VBD lost_VBN the_DT wild_JJ type_NN
        allele_NN of_IN 
        Pten_NNP ,_, suggesting_VBG that_IN the_DT complete_JJ
        inactivation_NN of_IN 
        Pten_NNP function_NN provides_VBZ an_DT additional_JJ
        growth_NN advantage_NN to_TO these_DT tumors_NNS ._. LOH_NNP at_IN the_DT 
        Pten_NNP locus_JJ has_VBZ recently_RB been_VBN reported_VBN
        in_IN mammary_JJ tumors_NNS arising_VBG in_IN 
        Pten_NNP heterozygous_JJ mice_NNS [_NN 26_CD ]_NN ,_, but_CC
        only_RB 4_CD %_NN of_IN the_DT mice_NNS developed_VBD tumors_NNS before_IN the_DT age_NN of_IN 30_CD
        weeks_NNS ,_, and_CC ,_, in_IN our_PRP$ cross_NN ,_, none_NN of_IN the_DT 
        Pten_NNP +_NN /_NN -_: mice_NNS without_IN the_DT 
        Wnt-_NNP 1_CD transgene_NN had_VBD a_DT palpable_JJ
        mammary_JJ tumor_NN before_IN the_DT age_NN of_IN 30_CD weeks_NNS ._. LOH_NNP at_IN the_DT 
        Pten_NNP locus_JJ has_VBZ also_RB been_VBN reported_VBN in_IN
        adrenal_NN and_CC lymphatic_JJ tumors_NNS ,_, but_CC not_RB in_IN uterine_NN tumors_NNS and_CC
        prostate_NN lesions_NNS in_IN 
        Pten_NNP +_NN /_NN -_: mice_NNS [_NN KP_NNP &_CC RP_NNP ,_,
        submitted_VBN ;_: 38_CD ]_NN ._.
        Activated_NNP AKT_NNP was_VBD more_RBR abundant_JJ in_IN tumors_NNS that_WDT were_VBD 
        Wnt-_NNP 1_CD TG_NNP ,_, 
        Pten_NNP +_NN /_NN -_: with_IN LOH_NNP ,_, as_IN has_VBZ been_VBN shown_VBN
        for_IN uterine_NN tumors_NNS in_IN 
        Pten_NNP heterozygous_JJ mice_NNS (_( KP_NNP ,_, RP_NNP ,_,
        submitted_VBN )_) ._. The_DT presence_NN of_IN areas_NNS unstained_JJ with_IN antibody_NN
        specific_JJ for_IN phosphorylated_JJ AKT_NNP suggests_VBZ that_IN additional_JJ
        factors_NNS other_JJ than_IN Pten_NNP may_MD influence_VB the_DT activation_NN of_IN
        AKT_NNP ._.
        Neither_DT apoptosis_NNS nor_CC proliferation_NN ,_, as_IN determined_VBN by_IN
        the_DT TUNEL_NNP assay_NN and_CC KI_NNP 67_CD staining_VBG ,_, was_VBD significantly_RB
        different_JJ between_IN tumors_NNS heterozygous_JJ for_IN 
        Pten_NNP (_( with_IN or_CC without_IN LOH_NNP )_) and_CC those_DT
        without_IN a_DT 
        Pten_NNP defect_NN ._. This_DT result_NN may_MD seem_VB
        paradoxical_JJ since_IN increased_VBN phosphorylated_JJ AKT_NNP ,_, due_JJ to_TO
        inactivation_NN of_IN 
        Pten_NNP ,_, suppresses_NNS apoptosis_NNS and_CC
        promotes_VBZ proliferation_NN ._. However_RB ,_, tumors_NNS in_IN 
        Wnt-_NNP 1_CD TG_NNP mice_NNS in_IN a_DT wild_JJ type_NN 
        Pten_NNP background_NN already_RB have_VBP highly_RB
        suppressed_VBN apoptosis_NNS and_CC accelerated_VBD proliferation_NN rates_NNS ,_,
        and_CC any_DT incremental_JJ changes_NNS ,_, if_IN present_JJ ,_, may_MD be_VB difficult_JJ
        to_TO detect_VB with_IN our_PRP$ current_JJ assays_NNS ._. Nonetheless_RB ,_, a_DT seemingly_RB
        minor_JJ difference_NN in_IN either_DT apoptosis_NNS or_CC proliferation_NN could_MD
        have_VB a_DT dramatic_JJ impact_NN on_IN tumor_NN growth_NN over_IN time_NN ._.
        Accelerated_NNP appearance_NN of_IN mammary_JJ adenocarcinomas_NNS in_IN the_DT
        presence_NN of_IN a_DT 
        Pten_NNP mutation_NN suggests_VBZ a_DT synergy_NN
        between_IN 
        Pten_NNP inactivation_NN and_CC the_DT 
        Wnt-_NNP 1_CD transgene_NN ._. The_DT apparent_JJ
        cooperation_NN of_IN these_DT two_CD genetic_JJ factors_NNS is_VBZ further_RBR
        strengthened_VBN by_IN our_PRP$ finding_VBG that_IN the_DT majority_NN of_IN tumors_NNS
        arising_VBG in_IN a_DT 
        Pten_NNP +_NN /_NN -_: background_NN have_VBP lost_VBN the_DT
        wild_JJ type_NN allele_NN ._. To_TO date_NN ,_, heterozygous_JJ inactivation_NN of_IN any_DT
        of_IN the_DT other_JJ tumor_NN suppressor_NN genes_NNS implicated_VBN in_IN breast_NN
        cancer_NN ,_, including_VBG 
        P_NN 53_CD ,_, Brca_NNP 1_CD ,_, Brca_NNP 2_CD ,_, and_CC 
        Rb_NNP ,_, has_VBZ failed_VBN to_TO cooperate_VB with_IN 
        Wnt-_NNP 1_CD in_IN promoting_VBG the_DT appearance_NN of_IN
        mammary_JJ tumors_NNS [_NN reviewed_VBN in_IN ref_NN ._. 39_CD ]_NN ._. Therefore_RB ,_, it_PRP is_VBZ
        possible_JJ that_IN the_DT signal_NN pathway_NN controlled_VBN by_IN 
        Pten_NNP is_VBZ one_CD of_IN the_DT preferred_JJ partners_NNS
        of_IN the_DT 
        Wnt-_NNP 1_CD pathway_NN in_IN cancer_NN progression_NN ,_,
        although_IN it_PRP remains_VBZ possible_JJ that_IN LOH_NNP at_IN the_DT 
        Pten_NNP locus_JJ is_VBZ more_RBR likely_JJ to_TO occur_VB
        than_IN for_IN the_DT other_JJ alleles_NNS crossed_VBN into_IN 
        Wnt-_NNP 1_CD TG_NNP mice_NNS ._. Even_RB though_IN 
        Wnt-_NNP 1_CD has_VBZ not_RB been_VBN directly_RB
        implicated_VBN in_IN human_JJ cancers_NNS ,_, many_JJ components_NNS of_IN the_DT Wnt_NNP
        signaling_VBG pathway_NN (_( such_JJ as_IN β-catenin_JJ ,_, APC_NNP ,_, 
        c-myc_JJ ,_, and_CC 
        cyclin_NN D_NNP 1_LS )_) are_VBP involved_VBN in_IN human_JJ
        tumors_NNS including_VBG breast_NN cancer_NN [_NN reviewed_VBN in_IN ref_NN ._. 40_CD ]_NN ._.
        One_CD of_IN the_DT goals_NNS of_IN mouse_NN modeling_NN efforts_NNS is_VBZ to_TO provide_VB
        an_DT opportunity_NN for_IN pre-clinical_JJ testing_NN of_IN generalized_JJ or_CC
        mechanism-specific_JJ therapeutics_NNS in_IN a_DT defined_VBN genetic_JJ
        setting_NN ._. Many_JJ human_JJ breast_NN tumors_NNS have_VBP reduced_VBN levels_NNS of_IN
        PTEN_NNP ,_, hence_RB inhibitors_NNS of_IN the_DT cell_NN signaling_VBG pathways_NNS
        affected_VBN by_IN PTEN_NNP could_MD be_VB tested_VBN in_IN the_DT model_NN we_PRP have_VBP
        developed_VBN ._. One_CD such_JJ candidate_NN is_VBZ the_DT rapamycin_NN analog_NN
        CCI_NNP 779_CD ,_, which_WDT has_VBZ been_VBN suggested_VBN to_TO inhibit_VB the_DT AKT_NNP
        signaling_VBG pathway_NN ,_, probably_RB through_IN inhibition_NN of_IN mTOR_NN
        (_( target_NN of_IN rapamycin_NN )_) ,_, a_DT potential_JJ target_NN of_IN AKT_NNP [_NN reviewed_VBN
        in_IN ref_NN ._. 41_CD ]_NN ._. CCI_NNP 779_CD has_VBZ been_VBN shown_VBN to_TO have_VB inhibitory_NN
        effects_NNS on_IN the_DT growth_NN of_IN 
        Pten_NNP -_: deficient_NN tumors_NNS in_IN the_DT uterus_NN
        and_CC prostate_NN in_IN mice_NNS (_( KP_NNP &_CC RP_NNP ,_, submitted_VBN ;_: M_NNP ._. Neshat_NNP
        &_CC C_NNP ._. Sawyers_NNP ,_, submitted_VBN )_) ._. Since_IN tumors_NNS arise_VBP rapidly_RB
        after_IN a_DT copy_NN of_IN 
        Pten_NNP is_VBZ inactivated_JJ ,_, and_CC with_IN
        predictable_JJ kinetics_NNS ,_, this_DT model_NN may_MD be_VB useful_JJ for_IN testing_VBG
        the_DT efficacy_NN of_IN these_DT therapies_NNS ._.
        Results_NNS presented_VBN here_RB and_CC published_VBN earlier_JJR [_NN 15_CD ,_, 16_CD ,_,
        17_CD ,_, 18_CD ,_, 26_CD ]_NN have_VBP clearly_RB demonstrated_VBN the_DT significant_JJ
        impact_NN of_IN 
        Pten_NNP on_IN mammary_JJ oncogenesis_NNS ._. Future_JJ
        testing_NN will_MD examine_VB the_DT tumorigenic_JJ effects_NNS caused_VBN by_IN
        other_JJ kinds_NNS of_IN genetic_JJ damage_NN in_IN the_DT signaling_VBG pathways_NNS
        affected_VBN by_IN Pten_NNP ._. The_DT TVA-directed_NNP gene_NN delivery_NN system_NN
        [_NN reviewed_VBN in_IN ref_NN ._. 42_CD ]_NN can_MD be_VB used_VBN to_TO introduce_VB viral_JJ
        vectors_NNS carrying_VBG genes_NNS encoding_VBG an_DT activated_VBN form_NN of_IN PI_NNP 3_CD K_NNP ,_,
        AKT_NNP ,_, or_CC candidate_NN substrates_NNS for_IN AKT_NNP into_IN the_DT mammary_JJ
        tissue_NN of_IN 
        Wnt-_NNP 1_CD TG_NNP mice_NNS ._. This_DT would_MD allow_VB the_DT
        testing_NN of_IN therapeutic_JJ interventions_NNS directed_VBN to_TO specific_JJ
        steps_NNS of_IN the_DT signaling_VBG pathway_NN regulated_VBN by_IN Pten_NNP ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Mice_NNS
          MMTV-_NNP 
          Wnt-_NNP 1_CD TG_NNP mice_NNS [_NN 27_CD ]_NN and_CC those_DT that_WDT
          carry_VBP a_DT mutant_JJ allele_NN of_IN 
          Pten_NNP [_NN 25_CD ]_NN have_VBP been_VBN described_VBN ._.
          Male_NNP 
          Wnt-_NNP 1_CD TG_NNP mice_NNS (_( a_DT mixture_NN of_IN FVB_NNP ,_,
          SJL_NNP ,_, and_CC C_NNP 57_CD BL_NNP /_NN 6_CD )_) were_VBD crossed_VBN with_IN 
          Pten_NNP heterozygous_JJ females_NNS (_( a_DT
          mixture_NN of_IN C_NNP 57_CD BL_NNP /_NN 6_CD and_CC 129_CD SvJ_NNP )_) to_TO generate_VB all_DT three_CD
          genotypes_NNS used_VBN in_IN this_DT paper_NN :_: 
          Wnt-_NNP 1_CD TG_NNP ,_, 
          Pten_NNP +_NN /_NN -_: ;_: 
          Wnt-_NNP 1_CD TG_NNP ,_, 
          Pten_NNP +_NN /_NN +_NN ;_: and_CC 
          Pten_NNP +_NN /_NN -_: ._. Genotyping_NNP for_IN the_DT 
          Wnt-_NNP 1_CD transgene_NN was_VBD done_VBN using_VBG PCR_NNP
          as_IN described_VBN [_NN 27_CD ]_NN ;_: PCR_NNP using_VBG primers_NNS from_IN the_DT neo_NN
          cassette_NN was_VBD performed_VBN to_TO detect_VB the_DT 
          Pten_NNP knockout_NN allele_NN ._. Mice_NNS were_VBD
          monitored_VBN weekly_JJ for_IN tumor_NN formation_NN by_IN visual_JJ inspection_NN
          and_CC /_NN or_CC palpation_NN ;_: most_JJS tumors_NNS were_VBD found_VBN when_WRB they_PRP were_VBD
          approximately_RB 0_CD ._. 5_CD cm_NN ._. Most_JJS of_IN tumors_NNS were_VBD harvested_VBN for_IN
          further_RBR analysis_NN when_WRB they_PRP were_VBD 1_CD ._. 5_CD cm_NN in_IN diameter_NN ._.
          Tissues_NNPS were_VBD fixed_VBN in_IN 10_CD %_NN buffered_JJ formalin_NN and_CC
          paraffin-embedded_JJ ._. For_IN histological_JJ survey_NN ,_, one_CD H-E_NNP
          section_NN per_IN block_NN was_VBD analyzed_VBN ._.
        
        
          Immunohistochemical_NNP staining_VBG and_CC TUNEL_NNP assay_NN
          Formalin-fixed_NNP and_CC paraffin-embedded_JJ sections_NNS were_VBD
          deparaffined_JJ and_CC rehydrated_JJ in_IN several_JJ changes_NNS of_IN xylene_NN ,_,
          ethanol_NN ,_, and_CC water_NN ._. Antigen-unmasking_NNP was_VBD achieved_VBN by_IN
          boiling_VBG the_DT slides_NNS for_IN 15_CD minutes_NNS in_IN citrate_NN buffer_NN ,_, pH_NN
          6_CD ._. 0_CD ,_, or_CC 1_CD mM_NN EDTA_NNP ._. Endogenous_NNP peroxidase_NN activity_NN was_VBD
          inactivated_JJ by_IN a_DT 5_CD minute_NN incubation_NN in_IN 3_CD %_NN hydrogen_NN
          peroxide_NN ,_, when_WRB needed_VBN ._. Immunohistochemical_NNP stainings_NNS were_VBD
          performed_VBN using_VBG Vector_NNP ABC_NNP kits_NNS (_( Vector_NNP Laboratories_NNPS )_)
          following_VBG the_DT manufacturer_NN 's_POS recommendations_NNS and_CC as_IN
          described_VBN [_NN 25_CD ]_NN ._. Rabbit_NNP antibodies_NNS against_IN Pten_NNP ,_, Ki_NNP 67_CD ,_,
          and_CC AKT_NNP phosphorylated_JJ at_IN Ser_NNP 473_CD were_VBD from_IN Neomarkers_NNP ,_,
          Dako_NNP ,_, and_CC New_NNP England_NNP BioLabs_NNP ,_, respectively_RB ._. The_DT TUNEL_NNP
          assay_NN was_VBD performed_VBN as_IN described_VBN [_NN 25_CD ]_NN ._.
        
        
          Southern_JJ hybridization_NN
          DNAs_NNP extracted_VBD from_IN tissues_NNS and_CC tumors_NNS were_VBD digested_VBN
          with_IN 
          Pst_NNP I_PRP ,_, followed_VBN by_IN electrophoresis_NNS ,_,
          and_CC blotted_JJ to_TO Nylon_NNP +_NN membrane_NN ._. Hybridization_NNP was_VBD done_VBN in_IN
          ExpressHyb_NNP solution_NN (_( Clontech_NNP )_) at_IN 60_CD °_NN C_NNP using_VBG a_DT 32_CD P_NN
          dCTP-labeled_JJ probe_NN that_WDT was_VBD synthesized_JJ from_IN a_DT 0_CD ._. 9_CD Kb_NNP
          template_NN located_VBN in_IN intron_NN 5_CD of_IN 
          Pten_NNP [_NN 25_CD ]_NN using_VBG the_DT RTS_NNP RadPrime_NNP
          DNA_NNP labeling_VBG system_NN (_( Life_NNP Technologies_NNPS )_) ._. The_DT probe_NN was_VBD
          incubated_JJ with_IN Cot-_NNP 1_CD DNA_NNP (_( Life_NNP Technologies_NNPS )_) at_IN 70_CD °_NN C_NNP for_IN
          10_CD minutes_NNS before_IN addition_NN to_TO the_DT hybridization_NN
          solution_NN ._.
        
      
    
  
